Showing results (31-40 of 408) with videos related to
Sort By:
Pageof 41
The American Journal of Dermatopathology|August 22, 2019
Primary Cutaneous Acral CD8+ T-Cell Lymphoma-A Single Center Review of 3 Cases and Recent Literature ReviewLeonardo A Tjahjono, Mark D P Davis, Thomas E Witzig, et al.Medicine|July 16, 2003
Gamma-heavy chain disease: review of 23 casesDietlind L Wahner-Roedler, Thomas E Witzig, Laura L Loehrer, et al.Blood|April 26, 2003
Expression of CD52 on plasma cells in plasma cell proliferative disordersShaji Kumar, Teresa K Kimlinger, John A Lust, et al.Leukemia & Lymphoma|November 29, 2013
Therapeutic options for patients with lymphoma and liver dysfunction or failure during mechlorethamine shortageMohamad Bassam Sonbol, Vishal Rana, S Sirop Kenderian, et al.Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|January 20, 2016
Asthma and orbital immunoglobulin G4-related diseaseMisbah Baqir, James A Garrity, Robert Vassallo, et al.The Journal of Adolescent Health : Official Publication of the Society for Adolescent Medicine|December 12, 2018
Effectiveness of the Adolescent Medicine Rotation in Improving Pediatric Residents Self-Assessed Skill and Confidence Caring for YouthEmily Ruedinger, Kristen Carlin, David Inwards-Breland, et al.Clinical Lymphoma, Myeloma & Leukemia|May 9, 2022
Leukemic High Grade B Cell Lymphoma is Associated With MYC Translocation, Double Hit/Triple Hit Status, Transformation, and CNS Disease Risk: The Mayo Clinic ExperienceJustin J Kuhlman, Muhamad Alhaj Moustafa, Liuyan Jiang, et al.Cancer Research|June 11, 2009
Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin's lymphomaZhi-Zhang Yang, Anne J Novak, Steven C Ziesmer, et al.Blood|July 7, 2007
CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cellsZhi-Zhang Yang, Anne J Novak, Steven C Ziesmer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2002
Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphomaStephen M Ansell, Kay M Ristow, Thomas M Habermann, et al.Pageof 41